Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2026-09-09 16:13:27 ET · period of report 2026-09-04 · accession 0001842190-26-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-09 16:13 | 2026-09-04 | TARS | Lin Elizabeth Yeu | Chief Medical Off | S - Sale | $87.50 | -10.8K | 2,547 | -81% | -$942.6K |
| MTI | 2026-09-09 16:13 | 2026-09-04 | TARS | Lin Elizabeth Yeu | Chief Medical Off | S - Sale | $87.50 | -3,180 | 1,590 | -67% | -$278.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-04 | S | D | 5,387 | $85.00 | 7,933 | D | — | — | (F1) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026. |
| 2 | Common | Common Stock | 2026-09-04 | S | D | 5,386 | $90.00 | 2,547 | D | — | — | (F1) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026. |
| 3 | Common | Common Stock | 2026-09-04 | S | D | 1,590 | $85.00 | 3,180 | I By Spouse's Roth IRA | — | — | (F2) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026. |
| 4 | Common | Common Stock | 2026-09-04 | S | D | 1,590 | $90.00 | 1,590 | I By Spouse's Roth IRA | — | — | (F2) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026. |